Definition/General

Introduction:
-Phyllodes tumor with carcinoid is an extraordinarily rare malignant phyllodes tumor where the stromal component contains carcinoid tumor (neuroendocrine neoplasm)
-This represents one of the most unusual forms of heterologous phyllodes tumor with neuroendocrine differentiation.
Origin:
-Develops from intralobular breast stroma with neuroendocrine differentiation
-May arise through transdifferentiation of stromal cells or ectopic development of neuroendocrine cells within phyllodes tumor.
Classification:
-WHO Classification categorizes this as malignant phyllodes tumor with heterologous elements
-Carcinoid component shows characteristic neuroendocrine markers and possible well-differentiated neuroendocrine tumor features.
Epidemiology:
-Exceptionally rare with fewer than 5 cases reported in medical literature
-Peak age 40-70 years
-Female predominance
-Clinical behavior depends on both components.

Clinical Features

Presentation:
-Large, slowly to rapidly growing breast mass
-May be associated with carcinoid syndrome if functional
-Usually asymptomatic initially.
Symptoms:
-Progressive breast enlargement
-Possible carcinoid syndrome (flushing, diarrhea, wheezing) if hormonally active
-Breast pain variable
-Constitutional symptoms possible.
Risk Factors:
-Previous phyllodes tumor history
-MEN1 syndrome (rare association)
-Family history of neuroendocrine tumors
-Advanced age.
Screening:
-No specific screening available
-Clinical examination for masses
-Assessment for carcinoid syndrome symptoms
-Biochemical markers if symptomatic.

Master Phyllodes Tumor with Carcinoid Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-Large, well-circumscribed to partially circumscribed mass
-Cut surface shows gray-white to tan areas with possible yellow foci
-Firm to soft consistency.
Characteristics:
-Size typically >5 cm (range 3-15 cm)
-Variable consistency
-May have lobulated appearance
-Focal hemorrhage or necrosis possible.
Size Location:
-Can occur in any breast region
-Usually involves significant breast tissue
-Unilateral presentation typical
-Rarely extends beyond breast.
Multifocality:
-Typically unifocal mass
-Multifocal carcinoid areas within tumor possible
-Satellite lesions rare
-Local extension uncommon.

Microscopic Description

Histological Features:
-Biphasic tumor with epithelial and mesenchymal components
-Carcinoid areas show typical neuroendocrine architecture with uniform cells in nests, ribbons, or trabecular pattern.
Cellular Characteristics:
-Uniform small to medium-sized cells with round to oval nuclei
-Finely granular chromatin (salt-and-pepper)
-Moderate eosinophilic cytoplasm
-Low to moderate mitotic activity.
Architectural Patterns:
-Nested, trabecular, or ribbon-like growth pattern
-Insular arrangement typical
-Organoid pattern possible
-Rich capillary network.
Grading Criteria:
-Well-differentiated neuroendocrine tumor (Grade 1: <2 mitoses/10 HPF, <3% Ki-67)
-Intermediate grade possible (Grade 2: 2-20 mitoses/10 HPF, 3-20% Ki-67).

Immunohistochemistry

Positive Markers:
-Chromogranin A positive
-Synaptophysin positive
-CD56/NCAM positive
-Neuron-specific enolase positive
-Epithelial component: CK7+, EMA+.
Negative Markers:
-TTF-1 negative (distinguishes from lung primary)
-CDX2 variable
-CK20 negative
-Thyroglobulin negative
-Calcitonin negative.
Diagnostic Utility:
-Chromogranin A and synaptophysin confirm neuroendocrine differentiation
-CD56 supportive
-TTF-1 negativity helps exclude lung metastasis.
Molecular Subtypes:
-Well-differentiated neuroendocrine tumor
-Intermediate-grade neuroendocrine tumor
-Functioning vs non-functioning carcinoid.

Molecular/Genetic

Genetic Mutations:
-MEN1 gene mutations (if associated with MEN1 syndrome)
-ATRX mutations possible
-DAXX mutations
-Chromosome 11q loss possible.
Molecular Markers:
-Low Ki-67 proliferation index (<3% for Grade 1)
-Neuroendocrine gene expression profile
-Chromogranin A and synaptophysin co-expression.
Prognostic Significance:
-Grade and Ki-67 index most important prognostic factors
-Size >2 cm may predict worse outcome
-Functional status affects quality of life.
Therapeutic Targets:
-Somatostatin receptor imaging and therapy (if receptor positive)
-mTOR inhibitors (everolimus)
-VEGF inhibitors
-Peptide receptor radionuclide therapy.

Differential Diagnosis

Similar Entities:
-Primary breast carcinoid
-Metastatic carcinoid to breast
-Solid papillary carcinoma with neuroendocrine features
-Invasive carcinoma with neuroendocrine differentiation.
Distinguishing Features:
-Phyllodes with carcinoid: Leaf-like areas, neuroendocrine markers
-Primary carcinoid: No phyllodes component
-Metastatic: Clinical history, other sites.
Diagnostic Challenges:
-Recognition of neuroendocrine features
-Distinction from metastatic carcinoid
-Assessment of phyllodes components
-Grading of neuroendocrine component.
Rare Variants:
-Atypical carcinoid (Grade 2)
-Large cell neuroendocrine carcinoma
-Mixed neuroendocrine-non-neuroendocrine neoplasm.

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen Information

[specimen type], measuring [size] cm in greatest dimension

Diagnosis

[diagnosis name]

Classification

Classification: [classification system] [grade/type]

Histological Features

Shows [architectural pattern] with [nuclear features] and [mitotic activity]

Size and Extent

Size: [X] cm, extent: [local/regional/metastatic]

Margins

Margins are [involved/uninvolved] with closest margin [X] mm

Lymphovascular Invasion

Lymphovascular invasion: [present/absent]

Lymph Node Status

Lymph nodes: [X] positive out of [X] examined

Special Studies

IHC: [marker]: [result]

Molecular: [test]: [result]

[other study]: [result]

Prognostic Factors

Prognostic factors: [list factors]

Final Diagnosis

Final diagnosis: [complete diagnosis]